STRATA Skin Sciences to Participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology firm specializing in dermatologic treatments, will participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference on May 21-22, 2024. The event will feature Dr. Dolev Rafaeli, CEO, and Christopher Lesovitz, CFO, who will be available for one-on-one meetings. Interested investors can register on Benchmark’s website or contact IR@strataskin.com to arrange a meeting. This participation aims to provide insights into the company's current activities and future plans.
- Participation in a notable investor conference could boost investor confidence and attract potential investors.
- Opportunity for direct interaction between company executives and investors, allowing for detailed discussions and relationship building.
- The event may provide a platform to showcase the company's innovation in dermatologic treatments, potentially generating positive interest.
- No new financial or clinical data was presented in the PR, limiting the immediate informational value to investors.
- The press release lacks detailed updates on the company's financial performance or specific business developments.
HORSHAM, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and Chief Executive Officer, and Christopher Lesovitz, Chief Financial Officer, will participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference being held on May 21 – 22, 2024.
To register, please visit the event page on Benchmark’s website: https://www.benchmarkcompany.com/4th-annual-healthcare-house-call-conference/
Dr. Rafaeli and Mr. Lesovitz will be available for one-on-one meetings on both days of the conference. Investors can also contact IR@strataskin.com to arrange a meeting.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System. STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell an acne treatment device and to integrate that device into its product offerings, the Company’s ability to develop, launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to dermatologist marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
ir@strataskin.com
FAQ
When will STRATA Skin Sciences participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference?
Who from STRATA Skin Sciences will be available for meetings at the Benchmark Healthcare House Call Conference?
How can investors arrange a meeting with STRATA Skin Sciences at the Benchmark Healthcare House Call Virtual 1x1 Investor Conference?
What is the stock symbol for STRATA Skin Sciences?
